As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab-relatlimab for untreated advanced or metastatic melanoma.
Following information received from the company the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2022.